ALBO ALBO

Albireo Pharma Stock Price

23.78
0.84 (3.66%)
Upgrade to Real-Time
Afterhours (Closed)
23.78
Volume 147,420
Bid Price 22.70
Ask Price 25.75
News -
Day High 24.00

Low
16.02

52 Week Range

High
37.63

Day Low 22.45
Company Name Stock Ticker Symbol Market Type
Albireo Pharma Inc ALBO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.84 3.66% 23.78 16:47:08
Open Price Low Price High Price Close Price Prev Close
22.70 22.45 24.00 23.78 22.94
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,555 147,420 $ 23.57 $ 3,474,080 - 16.02 - 37.63
Last Trade Time Type Quantity Stock Price Currency
16:15:40 7 $ 23.78 USD

Period:

Draw Mode:

Albireo Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 492.28M 20.70M 15.85M $ 40.58M $ -32.83M -1.86 -3.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -423.13k 19.70%

more financials information »

Albireo Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALBO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week21.8824.0021.1522.03103,9411.908.68%
1 Month21.9624.0018.0621.43177,7591.828.29%
3 Months18.3125.9716.4220.08360,6095.4729.87%
6 Months19.5426.9616.0220.14332,7034.2421.7%
1 Year23.1337.6316.0223.61303,3930.652.81%
3 Years22.7552.9011.2628.51226,9741.034.53%
5 Years24.4352.9011.2628.75159,019-0.65-2.66%

Albireo Pharma Description

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.